94-73-5

Basic information

• Product Name: 1,3-Benzenediamine,4-propyl-(9CI)
• Synonyms: 1,3-Benzenediamine,4-propyl-(9CI)
• CAS NO: 94-73-5
• Molecular Formula: C₉H₁₄N₂
• Molecular Weight: 150.22
• Product Categories: AMINEPRIMARY
• Mol File: 94-73-5.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 453.8°Cat760mmHg
• Flash Point: 228.2°C
• Appearance: /
• Density: 1.55g/cm³
• Vapor Pressure: 2.01E-08mmHg at 25°C
• Refractive Index: 1.81
• CAS DataBase Reference: 1,3-Benzenediamine,4-propyl-(9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 1,3-Benzenediamine,4-propyl-(9CI)(94-73-5)
• EPA Substance Registry System: 1,3-Benzenediamine,4-propyl-(9CI)(94-73-5)

Safety Data

• Hazardous Substances Data: 94-73-5(Hazardous Substances Data)

Usage

Chemical class

Aromatic amines

Applications

Used in the production of dyes, polymers, and pharmaceuticals

Physical appearance

Pale yellow to brown solid

Melting point

80-84°C

Toxicity

Low toxicity

Acute toxicity

Not expected to be acutely toxic by ingestion, inhalation, or skin contact

Safety precautions

Handle with care and follow all safety guidelines when working with this chemical

InChI:InChI=1/C10H11N5/c11-9-8-10(13-5-12-9)15(6-14-8)7-3-1-2-4-7/h3,5-6H,1-2,4H2,(H2,11,12,13)

Upstream product

• 93007-81-9 N-(2-propylphenyl)benzamide 
• 1821-39-2 2-propylaniline 
• 24503-35-3 2,4-dinitro-1-propylbenzene 
• 103-65-1 phenylpropane 
• 861532-14-1 benzoic acid-[2-(3-iodo-propyl)-anilide] 
• 72635-75-7 5-nitro-2-propyl-aniline 

Relevant articles and documents

NEW COMPOUND

PROBLEM TO BE SOLVED: To provide a new compound that does not have structural similarity to ceramide and has excellent CERT inhibitory activity. SOLUTION: The present invention provides a new compound of structural formula (I). A bond group -X- is cis-cyclopropyl-, R1, R2, R3, R4, and R5 independently represent a hydrogen atom, a halogen atom, a linear or branched C1-C8 alkyl group that may have a halogen atom, or OR6. SELECTED DRAWING: Figure 1 COPYRIGHT: (C)2020,JPOandINPIT

COMPOSITIONS FOR TREATMENT OF CYSTIC FIBROSIS AND OTHER CHRONIC DISEASES

The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.